Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: A proposed method

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 10, 2009, Pages 1078-1086

  Murphy, S J ^a   Wang, L ^b   Anderson, L A ^c   Steinlauf, A ^b   Present, D H ^b   Mechanick, J I ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; DEXAMETHASONE;

ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORTICOTROPIN TEST; CROHN DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS; WITHDRAWAL SYNDROME;

ADRENAL CORTEX HORMONES; ADULT; AGED; DEXAMETHASONE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 71949108143     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04136.x     Document Type: Article

References (36)

1. Summers RW, Switz DM, Sessions JT Jr., et al. National cooperative crohn's disease study: results of drug treatment. Gastroenterology 1979 77 (4 Pt 2 847 869.
2. Malchow H, Ewe K, Brandes JW, et al. European cooperative crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984 86 : 249 266.
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955 2 : 1041 1048.
4. Orth DN, Kovacs WJ, DeBold CR. The adrenal cortex. In : Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology, 8th edn. Philadelphia, USA : W. B. Saunders Company, 1992 : 489.
5. Amatruda TT Jr., Hurst MM, D'Esopo ND. Certain endocrine and metabolic facets of the steroid withdrawal syndrome. J Clin Endocrinol Metab 1965 25 : 1207 1217.
6. Dixon RB, Christy NP. On the various forms of corticosteroid withdrawal syndrome. Am J Med 1980 68 : 224 230.
7. Royal College of Physicians UK IBD audit (available at: http://www.rcplondon.ac.uk/college/ceeu/ceeu-uk-ibd-audit.htm)
8. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 crohn's disease patients: results from a single centre cohort. Gut 2008 58 (4 492 500.
9. Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, groupe d'etudes therapeutiques des affections inflammatoires digestives. Gastroenterology 1996 110 : 688 693.
10. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in crohn's disease. Gut 1994 35 : 360 362.
11. Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev 2003 24 : 523 538.
12. Payne LC, Weigent DA, Blalock JE. Induction of pituitary sensitivity to interleukin-1: a new function for corticotropin-releasing hormone. Biochem Biophys Res Commun 1994 198 : 480 484.
13. Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in crohn's disease. Gut 2005 54 : 488 495.
14. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002 347 : 417 429.
15. Byyny RL. Withdrawal from glucocorticoid therapy. N Engl J Med 1976 295 : 30 2.
16. Tyrrell J. Glucocorticoid therapy. In : Felig P, Baxter J, Frohman L, eds. Endocrinology and Metabolism, 3rd edn. New York : McGraw-Hill Inc, 1995 : 855 882.
17. Present DH, Korelitz BI, Wisch N, et al. Treatment of crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980 302 : 981 987. (Pubitemid 10125406)
18. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of crohn's disease. Cochrane Database Syst Rev 2000 2 : CD000545.
19. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of crohn's disease. the north american crohn's study group investigators. N Engl J Med 1995 332 : 292 297.
20. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
21. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 2476. (Pubitemid 41770166)
22. Cohen RD, Tsang JF, Hanauer SB. Infliximab in crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000 95 : 3469 3477.
23. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for crohn's disease in clinical practice at the mayo clinic: the first 100 patients. Am J Gastroenterol 2001 96 : 722 729.
24. Hanauer SB, Meyers S. Management of crohn's disease in adults. Am J Gastroenterol 1997 92 : 559 566.
25. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. american college of gastroenterology, practice parameters committee. Am J Gastroenterol 1997 92 : 204 211.
26. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of crohn's disease: current management. Gut 2006 55 (Suppl 1 i16 35.
27. Bhattacharyya A, Kaushal K, Tymms DJ, et al. Steroid withdrawal syndrome after successful treatment of cushing's syndrome: a reminder. Eur J Endocrinol 2005 153 : 207 210.
28. Harter JG, Reddy WJ, Thorn GW. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963 269 : 591 596.
29. Fauci AS. Alternate-day corticosteroid therapy. Am J Med 1978 64 : 729 731.
30. Donald RA. Dexamethasone suppression of the plasma corticosterone response to stress in the rat. J Physiol 1966 182 : 603 611.
31. Sampson PA, Winstone NE, Brooke BN. Adrenal function in surgical patients after steroid therapy. Lancet 1962 2 : 322 325.
32. Treadwell BL, Salvage O, Sever ED, et al. Pituitary-adrenal function during corticosteroid therapy. Lancet 1963 1 : 355 358.
33. Schlaghecke R, Kornely E, Santen RT, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992 326 : 226 230.
34. Daly JR, Myles AB, Bacon PA, et al. Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis. Ann Rheum Dis 1967 26 : 18 25.
35. Desrame J, Sabate JM, Agher R, et al. Assessment of hypothalamic- pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease. Am J Gastroenterol 2002 97 : 1785 1791.
36. LaRochelle GE Jr., LaRochelle AG, Ratner RE, et al. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993 95 : 258 264.